Top 10 ASX Dividend Stocks for Nov 2026 Download Free Report

Rafael Holdings, Inc.

Company price
0.9197 USD 0.02 ( 2.19%)
Last update at 2026-11-20T21:00:00Z
VOLUME
156478
Market Cap
111.28M

Momentum Score

…

Rafael Holdings, Inc. primarily engages in holding interests in clinical and early-stage pharmaceutical companies, and medical devices in the United States and Israel. It operates in three segments, Healthcare, Infusion Technology, and Real Estate. The company engages in the development and commercialization of therapies that exploit the metabolic differences between normal cells and cancer cells. Its lead drug candidate is Trappsol Cyclo, which is in phase 3 clinical trial being evaluated for the potential treatment of Niemann-Pick Disease Type C1 (NPC1), a rare, fatal and progressive genetic disorder; and CPI-613 (devimistat), a stable analog of normally transient, acylated catalytic intermediates of lipoate, which is in phase II of clinical trial. The company is also involved in developing Promitil, a molecule designed for the targeted delivery of mitomycin-C in a proprietary prodrug form, completed Phase 1A and 1B clinical studies targeting patients with advanced cancers. In addition, it engages in the development of surgical and procedural devices, including orthopedic arthroscopy instrument for Carpal Tunnel syndrome. Rafael Holdings, Inc. was incorporated in 2017 and is headquartered in Newark, New Jersey.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
0.78
Low
0.97
High
52 Week Price Range
1.12
Low
3.96
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

Public information on Rafael Holdings, Inc. (RFL) is limited; the company is described in public filings as a small, publicly traded holding company with interests in operating assets. Long-term growth may depend on management’s ability to acquire or improve portfolio companies and on successful execution of strategic transactions, which could support value appreciation for shareholders.

Risk Score
High

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
0.90
Dividend Yield
-
Revenue TTM
0.98M
Revenue Per Share
0.02
Gross Profit TTM
0.93M
Debt / Equity
0.01
ROE
-37.60%
Net Debt
-52.08M
ROCE
-31.74%
Diluted EPS TTM
-0.72

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-07-31 2024-07-31 2023-07-31 2022-07-31 2021-07-31
Type yearly yearly yearly yearly yearly
Date 2025-07-31 2024-07-31 2023-07-31 2022-07-31 2021-07-31
Income before tax -33.20M -67.68M -8.74M -139.97M -25.13M
Minority interest - 30.59M 0.34M 17.72M 14.42M
Net income -30.52M -34.41M -1.88M -124.66M -25.15M
Selling general administrative 13.78M 8.85M 8.93M 16.98M 20.42M
Gross profit 0.49M 0.48M 0.28M 0.41M 3.97M
Reconciled depreciation - 0.23M 0.08M 0.07M 1.46M
Ebit -32.54M -67.01M -17.59M 19.17M -29.81M
Ebitda -32.25M -66.79M -17.51M 19.24M -19.11M
Depreciation and amortization 0.29M 0.23M 0.08M 0.07M 10.70M
Operating income -26.11M -102.63M -15.04M 19.17M -29.81M
Other operating expenses 27.03M 103.26M 15.32M 60.89M 26.78M
Interest expense 0.66M 0.25M 0.00M 0.01M 0.10M
Tax provision -2.55M -2.68M -0.26M 0.00M 0.02M
Interest income 4.35M 2.38M 3.25M 0.20M 4.66M
Net interest income - 2.13M 3.25M 0.20M -0.10M
Extraordinary items - 0.00M 6.48M -1.83M -1.71M
Income tax expense -2.55M -2.68M -0.26M -15.31M 0.02M
Total revenue 0.92M 0.64M 0.28M 0.41M 3.97M
Total operating expenses 26.60M 103.11M 15.32M 60.89M 26.78M
Cost of revenue 0.42M 0.15M - - -
Total other income expense net -7.09M 34.94M 6.30M -159.14M 4.68M
Discontinued operations - - - -1.83M -1.71M
Net income from continuing ops - -65.00M -8.69M -140.55M -24.77M
Net income applicable to common shares -30.52M -34.41M -1.88M -124.66M -24.54M
Breakdown 2025-07-31 2024-07-31 2023-07-31 2022-07-31 2021-07-31
Type yearly yearly yearly yearly yearly
Date 2025-07-31 2024-07-31 2023-07-31 2022-07-31 2021-07-31
Total assets 114.11M 96.83M 98.83M 118.32M 154.06M
Intangible assets 32.57M 1.85M 1.57M 1.57M 1.57M
Other current assets 1.83M 0.43M 0.91M 44.81M 1.07M
Total liab 15.74M 10.57M 2.20M 21.11M 17.35M
Total stockholder equity 94.39M 82.19M 100.29M 100.52M 122.29M
Deferred long term liab - - - 1.57M 1.57M
Other current liab 4.09M 2.64M 1.81M 5.46M 0.25M
Common stock 0.52M 0.25M 0.24M 0.24M 0.18M
Capital stock - 0.25M 0.24M 0.24M 0.18M
Retained earnings -232.26M -201.74M -167.33M -165.46M -40.80M
Other liab - - - 0.09M 0.05M
Good will 19.94M 3.05M - - -
Other assets 1.43M 0.04M 0.01M 2.96M 10.59M
Cash 52.77M 2.67M 21.50M 26.54M 7.85M
Cash and equivalents 52.77M 2.67M 21.50M 26.54M 7.85M
Total current liabilities 11.60M 7.51M 2.15M 21.03M 17.30M
Current deferred revenue - - - - 1.36M
Net debt -52.08M -0.29M -21.50M -11.54M 6.67M
Short term debt 0.61M 2.31M 0.00M 15.00M 14.53M
Short long term debt - 2.31M - 15.00M 14.53M
Short long term debt total 0.69M 2.39M - 15.00M 14.53M
Other stockholder equity 321.99M 283.57M 264.01M 262.02M 159.14M
Property plant equipment 1.60M 2.12M 1.70M 1.77M 43.24M
Total current assets 56.71M 72.50M 82.94M 108.35M 14.76M
Long term investments - 12.01M 7.62M 0.48M 80.19M
Net tangible assets - - - 100.52M 122.29M
Short term investments 0.00M 63.27M 58.01M 36.70M 0.57M
Net receivables 1.83M 6.13M 2.52M 0.30M 0.83M
Long term debt 0.08M 0.07M - - -
Inventory 0.28M - - - 5.00M
Accounts payable 6.89M 2.56M 0.33M 0.56M 1.16M
Accumulated other comprehensive income 4.14M 0.11M 3.37M 3.70M 3.77M
Common stock total equity - - - - 0.18M
Non currrent assets other 1.43M 5.30M 0.01M 6.15M 1.52M
Non current assets total 57.39M 24.33M 15.89M 9.97M 139.29M
Long term debt total 0.08M 0.07M 0.00M 0.00M 0.00M
Breakdown 2025-07-31 2024-07-31 2023-07-31 2022-07-31 2021-07-31
Type yearly yearly yearly yearly yearly
Date 2025-07-31 2024-07-31 2023-07-31 2022-07-31 2021-07-31
Investments - -10.82M 21.21M -36.81M -8.17M
Change to liabilities - - - 0.05M 0.16M
Total cashflows from investing activities 44.03M -10.82M 21.21M -63.80M -8.17M
Net borrowings - -0.80M - - 15.00M
Total cash from financing activities 24.83M -0.18M -15.22M 103.86M 30.30M
Change to operating activities - - - -0.14M -0.99M
Net income -30.64M -65.00M -2.21M -140.55M -24.77M
Change in cash 50.09M -18.82M -5.04M 13.68M 6.65M
Begin period cash flow 2.67M 21.50M 26.54M 12.85M 6.21M
End period cash flow 52.77M 2.67M 21.50M 26.54M 12.85M
Total cash from operating activities -18.92M -7.80M -10.89M -26.08M -15.60M
Issuance of capital stock - - 0.00M 110.17M 13.00M
Depreciation 0.29M 0.23M 0.08M 0.07M 1.46M
Other cashflows from investing activities -19.67M -6.75M 21.21M -26.99M -0.50M
Change to inventory -0.01M - - - -1.13M
Change to account receivables 0.09M -0.29M -0.12M 0.07M -0.16M
Sale purchase of stock 25.00M -0.17M 0.00M 110.17M 15.07M
Other cashflows from financing activities -0.22M 0.79M -15.22M -6.30M 17.30M
Change to netincome - - - 98.52M 8.44M
Capital expenditures 0.00M 0.18M 51.68M 0.00M 0.21M
Change in working capital 0.97M -0.61M -0.09M -0.01M -0.99M
Stock based compensation 2.12M 2.30M 2.19M -0.92M 8.66M
Other non cash items 8.51M 55.29M -11.79M 115.32M 0.03M
Free cash flow -18.93M -7.98M 40.79M -26.08M -15.81M

Peer Comparison*

Sector: Real Estate Industry: Real Estate Services

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
RFL
Rafael Holdings, Inc.
0.02
2.19%
0.92 - - 113.55 1.50 85.18 5.39
CBRE
CBRE Group Inc Class A
-1.55
1.21%
126.77 38.92 21.37 1.09 4.95 1.28 25.73
BEKE
Ke Holdings Inc
0.07
0.39%
17.87 42.90 16.92 0.33 2.33 1.66 24.07
VNNVF
Vonovia SE
-0.34
1.81%
18.20 - 13.44 3.96 0.83 4.07 -3.05
VTAGY
Vantage Towers AG
-
-%
21.42 42.00 37.59 28.32 3.61 21.19 24.26

Profile*

Rafael Holdings, Inc.

Rafael Holdings, Inc. primarily engages in holding interests in clinical and early-stage pharmaceutical companies, and medical devices in the United States and Israel. It operates in three segments, Healthcare, Infusion Technology, and Real Estate. The company engages in the development and commercialization of therapies that exploit the metabolic differences between normal cells and cancer cells. Its lead drug candidate is Trappsol Cyclo, which is in phase 3 clinical trial being evaluated for the potential treatment of Niemann-Pick Disease Type C1 (NPC1), a rare, fatal and progressive genetic disorder; and CPI-613 (devimistat), a stable analog of normally transient, acylated catalytic intermediates of lipoate, which is in phase II of clinical trial. The company is also involved in developing Promitil, a molecule designed for the targeted delivery of mitomycin-C in a proprietary prodrug form, completed Phase 1A and 1B clinical studies targeting patients with advanced cancers. In addition, it engages in the development of surgical and procedural devices, including orthopedic arthroscopy instrument for Carpal Tunnel syndrome. Rafael Holdings, Inc. was incorporated in 2017 and is headquartered in Newark, New Jersey.

520 Broad Street, Newark, NJ, United States, 07102

212 658 1450

21

Name Title Year Born
Mr. Howard S. Jonas Founder & Chairman 1956
Mr. William Conkling Chief Exec. Officer 1972
Mr. Patrick Fabbio M.B.A. CFO & Pres 1968
Ms. Barbara A. Ryan Investor Relations Officer 1960
Mr. David A. Polinsky Esq. Chief of Staff 1972
Mr. Gus Kodersha Chief Technical Operations Officer NA
Dr. Rick Ewing Head of Drug Discovery NA
Ms. Joyce J. Mason Esq. Corp. Sec. 1959
Mr. Howard S. Jonas CEO, President, Founder & Executive Chairman 1956
Mr. David A. Polinsky Esq. Chief Financial Officer 1972

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Support

Hi! How can we help you today?

Loading…